



Express Mail No.: EL 500 578 574 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Taylor et al.

Confirmation No.: 8436

Serial No.: 09/724,620

Art Unit: 1642

Filed: November 28, 2000

Examiner: Canella, Karen A.

For: METHODS FOR THE
PREVENTION AND TREATMENT
OF CANCER USING ANTI-C3B(I)
ANTIBODIES

Attorney Docket No: 9426-048

TRANSMITTAL OF FORMAL DRAWINGS

Official Draftsperson

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir/Madam:

In response to the Notice of Draftsperson's Patent Drawing Review, mailed December 3, 2002, and in connection with the above-identified patent application, transmitted herewith are formal drawings for the present application. The formal drawings consist of FIGS. 1A through 10 (11 sheets of drawings).

Applicants respectfully request entry of the enclosed drawings into the file of the above-identified application.

Respectfully submitted,

Date: February 28, 2003

Geraldine F. Baldwin 31,232
Geraldine F. Baldwin (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

By: Jennifer J. Chedea
Reg No. 46,617



09724620

6572856




FIG. 1A




FIG. 1B




FIG.1C




FIG.1D




FIG.2A




FIG.2B




FIG.3A




FIG.3B




FIG.4




FIG.5A




FIG.5B



Docket No.: 9426-048-999
Serial No.: 09/724,620
Inventor(s): TAYLOR et al.
Title: "METHODS FOR THE PREVENTION
AND TREATMENT OF CANCER AND
INFECTIONS USING ANTI-C3b(i) ANTIBODIES"




FIG.6




FIG.7A




FIG.7B




FIG.8



Raji Cells Opsonized With Serum and Rituximab are Bound
to Erythrocytes via an Anti-CR1 X Anti-C3bi HP





FIG.9



Binding of Opsonized Raji Cells* to Erythrocytes
in the Presence of Rituximab and an
Anti-CR1 X Anti-C3bi HP



* Washed Whole Blood Reconstituted in Serum

FIG.10